Skip to content
Antimicrobial Peptides advanced

Colistin

Polymyxin lipopeptide antibiotic that disrupts gram-negative bacterial outer membranes, used as last-line therapy for MDR infections.

By Encyclopeptide Editorial | 2 min read
polymyxin lipopeptide antibiotic MDR gram-negative

Chemical Identity

PropertyValue
Chemical FormulaC52H98N16O13 (Colistin A)
Molecular Weight1155.4 Da
CAS Number1066-17-7 (sodium salt)
Peptide ClassCyclic Lipopeptide (Polymyxin family)
OriginPaenibacillus polymyxa subsp. colistinus
RouteIV, inhaled, topical

Structure

Colistin (polymyxin E) is a mixture of cyclic lipopeptides (colistin A and B) produced by Paenibacillus polymyxa. It consists of a heptapeptide ring with a tripeptide side chain acylated with a fatty acid. Colistin A has 6-methyloctanoic acid and colistin B has 6-methylheptanoic acid as the fatty acid component.

Mechanism of Action

Colistin binds to lipopolysaccharide (LPS) in the gram-negative outer membrane through electrostatic interaction between cationic diaminobutyric acid residues and anionic lipid A phosphate groups. The fatty acid tail displaces stabilizing divalent cations, disrupting membrane integrity and causing cell lysis. It also has some endotoxin-binding activity.

Clinical Applications

  • MDR gram-negative infections: Pseudomonas, Acinetobacter, Klebsiella carbapenemase producers
  • Ventilator-associated pneumonia: Inhaled colistin as adjunct
  • Cystic fibrosis: Inhaled for Pseudomonas exacerbations
  • Intrathecal/intraventricular: CNS infections with resistant gram-negatives

Pharmacokinetics

  • Half-life: 5-7 hours (colistin base)
  • Protein binding: ~50%
  • Elimination: Renal (primarily as inactive metabolites)
  • Loading dose: Required to achieve therapeutic levels
  • Route: IV (colistimethate sodium), inhaled, intrathecal

Safety and Side Effects

Nephrotoxicity (dose-limiting, 20-60%), neurotoxicity (paresthesias, dizziness, neuromuscular blockade, seizures), and hypersensitivity. Narrow therapeutic index. Colistimethate is less toxic than colistin sulfate.

References

  • Falagas, M.E., & Kasiakou, S.K. (2006). Colistin: the revival of polymyxins. Lancet Infectious Diseases, 6, 113-122.
  • Nation, R.L., & Li, J. (2009). Colistin: clinical pharmacology. Clinical Pharmacokinetics, 48, 623-637.

Test Your Knowledge

Reinforce what you learned about Colistin with interactive quizzes on Wikipept.

Take a Quiz on Wikipept